Amylyx Pharmaceuticals (AMLX) vs Enliven Therapeutics (ELVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 101.8% versus a gain of 100.0%. Amylyx Pharmaceuticals is the larger company by market cap ($3.41 billion vs $2.98 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | ELVN |
|---|---|---|
| Share price | $27.20 | $40.63 |
| Market cap | $3.41B | $2.98B |
| 1-day change | -0.84% | -1.76% |
| YTD return | +125.17% | +163.83% |
| 1-year return | +101.78% | +99.95% |
| 5-year return | — | +177.53% |
| EPS (TTM) | $-1.41 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-144.74M | $-103.69M |
| 52-week high | $41.14 | $62.32 |
| 52-week low | $10.83 | $14.79 |
| Distance from 52-week high | -33.88% | -34.80% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +55.74% | +81.32% |
| Average volume | 2.35M | 1.12M |
| Shares outstanding | 125.51M | 73.27M |
| Employees | 136 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
AMLX vs ELVN FAQ
Which is bigger, Amylyx Pharmaceuticals or Enliven Therapeutics?
Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.41B compared with $2.98B for Enliven Therapeutics (ELVN).
Which stock has performed better over the past year, AMLX or ELVN?
AMLX returned +101.78% over the past 12 months, compared with +99.95% for ELVN (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Enliven Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.